Growth Factors

AOD-9604

Evidence: moderate_human

Mechanism of Action

AOD-9604 is a synthetic 16-amino acid fragment (residues 176-191) of the C-terminal domain of human growth hormone with a tyrosine substitution at the N-terminus. It selectively stimulates lipolysis by upregulating beta-3 adrenergic receptors in adipose tissue while inhibiting lipogenesis. It modulates lipid and glucose metabolism through beta-adrenergic and AMPK-related pathways without influencing IGF-1 activity, growth, or insulin sensitivity — retaining GH's fat-burning properties without its growth-promoting effects.

Dosing Protocol

Standard: Research indicates 250-300 mcg daily via subcutaneous injection, administered in the morning on an empty stomach.

Maintenance: Research indicates 250 mcg daily for ongoing fat loss protocols.

Administration: subcutaneousoral

Timing: Morning administration on empty stomach, at least 30 minutes before eating. Fasted state enhances lipolytic effect.

Duration: 12-20 week cycles.

Notes

AOD-9604 completed six human clinical trials involving 900+ participants but failed to achieve statistical significance in its largest Phase IIb trial, leading to termination of pharmaceutical development in 2007. Despite this, it remains popular in the optimization community for body composition. Beta-3 adrenergic receptor knockout mice are unresponsive to AOD-9604, confirming the mechanism. It also shows promise for cartilage repair (osteoarthritis). Tirzepatide context: AOD-9604 addresses a narrower metabolic pathway than GLP-1 agonists; for comprehensive metabolic optimization, GLP-1 agonists offer stronger clinical evidence.

Stacking

  • 5-Amino-1MQ
  • MOTS-c
  • CJC-1295/Ipamorelin
  • Tesofensine

Interactions

  • Insulin [MEDIUM] — AOD-9604 modulates glucose metabolism; monitor blood glucose in diabetic patients.
  • HGH [LOW] — Redundant mechanisms — AOD-9604 mimics the lipolytic fragment of HGH.
  • Tirzepatide/Semaglutide [LOW] — Can be combined for enhanced metabolic optimization; complementary mechanisms.
  • May overlap with other GH-axis interventions

Contraindications

  • Active cancer
  • Pregnancy and breastfeeding
  • Type 1 diabetes (use with caution)
  • Limited human evidence and sourcing variability

Side Effects

  • Injection site reactions
  • Headache
  • Mild nausea
  • Transient hypoglycemia (rare)

Key Papers

  • 10.1210/endo.142.12.8589
  • 10.1038/sj.ijo.0803166
  • Body-composition literature on AOD-9604

Source Quality

Compounding pharmacy or research-grade supplier. Has GRAS status (Generally Recognized as Safe) in Australia for food applications.

Disclaimer: This information is for educational purposes only and is not medical advice. BioAccelera Labs does not diagnose, treat, or prescribe. Consult a licensed healthcare provider before using any compound.

Should AOD-9604 Be in Your Stack?

Take the free assessment and get personalized recommendations based on your biology and goals.

Get Your Free Protocolor take the assessment →
← Browse All 231 Compounds